Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

AIMS To evaluate the benefit of adding Losartan to baseline therapy in patients with Marfan syndrome (MFS). METHODS AND RESULTS A double-blind, randomized, multi-centre, placebo-controlled, add on trial comparing Losartan (50 mg when <50 kg, 100 mg otherwise) vs. placebo in patients with MFS according to Ghent criteria, age >10 years old, and receiving standard therapy. 303 patients, mean age 29.9 years old, were randomized. The two groups were similar at baseline, 86% receiving β-blocker therapy. The median follow-up was 3.5 years. The evolution of aortic diameter at the level of the sinuses of Valsalva was not modified by the adjunction of Losartan, with a mean increase in aortic diameter at the level of the sinuses of Valsalva of 0.44 mm/year (s.e. = 0.07) (-0.043 z/year, s.e. = 0.04) in patients receiving Losartan and 0.51 mm/year (s.e. = 0.06) (-0.01 z/year, s.e. = 0.03) in those receiving placebo (P = 0.36 for the comparison on slopes in millimeter per year and P = 0.69 for the comparison on slopes on z-scores). Patients receiving Losartan had a slight but significant decrease in systolic and diastolic blood pressure throughout the study (5 mmHg). During the study period, aortic surgery was performed in 28 patients (15 Losartan, 13 placebo), death occurred in 3 patients [0 Losartan, 3 placebo, sudden death (1) suicide (1) oesophagus cancer (1)]. CONCLUSION Losartan was able to decrease blood pressure in patients with MFS but not to limit aortic dilatation during a 3-year period in patients >10 years old. β-Blocker therapy alone should therefore remain the standard first line therapy in these patients.

[1]  S. Colan,et al.  Atenolol versus losartan in children and young adults with Marfan's syndrome. , 2014, The New England journal of medicine.

[2]  H. Connolly,et al.  Of Marfan's syndrome, mice, and medications. , 2014, The New England journal of medicine.

[3]  Deepak L. Bhatt,et al.  Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.

[4]  F. Hu,et al.  Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. , 2013, Mayo Clinic proceedings.

[5]  A. Hughes,et al.  Meta‐analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index , 2013, British journal of clinical pharmacology.

[6]  H. Krum,et al.  Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. , 2012, Circulation.

[7]  C. Ki,et al.  A comparison of the ghent and revised ghent nosologies for the diagnosis of marfan syndrome in an adult korean population , 2012, American journal of medical genetics. Part A.

[8]  E. Arbustini,et al.  The new Ghent criteria for Marfan syndrome: what do they change? , 2012, Clinical genetics.

[9]  F. Tubach,et al.  Aortic Event Rate in the Marfan Population: A Cohort Study , 2012, Circulation.

[10]  H. Dietz,et al.  Pravastatin Reduces Marfan Aortic Dilation , 2011, Circulation.

[11]  D. Judge,et al.  Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK Antagonism , 2011, Science.

[12]  Helmut Baumgartner,et al.  ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). , 2010, European heart journal.

[13]  P. Robinson,et al.  Congenital heart disease Cardiovascular manifestations in men and women carrying a FBN 1 mutation , 2010 .

[14]  C. van Breemen,et al.  Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome. , 2010, The Journal of thoracic and cardiovascular surgery.

[15]  Laurence Faivre,et al.  The revised Ghent nosology for the Marfan syndrome , 2010, Journal of Medical Genetics.

[16]  F. Tubach,et al.  Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. , 2010, Archives of cardiovascular diseases.

[17]  A. John Camm,et al.  The Esc Textbook of Cardiovascular Medicine , 2009 .

[18]  C. van Breemen,et al.  Long‐term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome , 2009, British journal of pharmacology.

[19]  E. O’Brien.  Renal sympathetic denervation for resistant hypertension , 2009, The Lancet.

[20]  G. Jondeau,et al.  Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 gene , 2009, European Journal of Human Genetics.

[21]  W. Nichols,et al.  Effects of Arterial Stiffness, Pulse Wave Velocity, and Wave Reflections on the Central Aortic Pressure Waveform , 2008, Journal of clinical hypertension.

[22]  G. Jondeau,et al.  Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. , 2007, The American journal of cardiology.

[23]  P Segers,et al.  Aortic reflection coefficients and their association with global indexes of wave reflection in healthy controls and patients with Marfan's syndrome. , 2006, American journal of physiology. Heart and circulatory physiology.

[24]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[25]  William Stewart,et al.  Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[26]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[27]  P. Engelfriet,et al.  Aortic root growth in men and women with the Marfan's syndrome. , 2005, The American journal of cardiology.

[28]  P. Boutouyrie,et al.  Central pulse pressure is a major determinant of ascending aorta dilation in Marfan syndrome. , 1999, Circulation.

[29]  A de Roos,et al.  Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. , 1998, The American journal of cardiology.

[30]  R E Pyeritz,et al.  Revised diagnostic criteria for the Marfan syndrome. , 1996, American journal of medical genetics.

[31]  J. Duranteau,et al.  Effects of the angiotensin type I receptor antagonist, losartan, on systemic and regional vascular responses to lower body negative pressure in healthy volunteers. , 1995, British journal of clinical pharmacology.

[32]  E. Murphy,et al.  Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. , 1994, The New England journal of medicine.

[33]  R. Devereux,et al.  Two-dimensional echocardiographic aortic root dimensions in normal children and adults. , 1989, The American journal of cardiology.

[34]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[35]  V. Aboyans,et al.  [2014 ESC Guidelines on the diagnosis and treatment of aortic diseases]. , 2014, Kardiologia polska.

[36]  J. Stockman,et al.  Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome , 2010 .

[37]  A. Evangelista,et al.  Diseases of the aorta and trauma to the aorta and heart , 2022 .